Nature Reviews. Drug Discovery最新文献_第9页

The race to reset autoimmune diseases 重置自身免疫性疾病的竞赛

IF 101.8 1区医学

Nature Reviews. Drug Discovery Pub Date : 2025-05-12 DOI: 10.1038/d41573-025-00085-z

Mayank Bhandari, Jeffrey F. Smith, Emily Capra, Guang Yang

引用次数: 0

Hinge modifier approach opens door to drugging HECT E3 ligases 铰链修饰剂方法为HECT E3连接的药物化打开了大门

IF 101.8 1区医学

Nature Reviews. Drug Discovery Pub Date : 2025-05-09 DOI: 10.1038/d41573-025-00084-0

Alex Eccleston

引用次数: 0

A liver-directed route to reverse allergies 一个肝脏导向的途径来逆转过敏

IF 101.8 1区医学

Nature Reviews. Drug Discovery Pub Date : 2025-05-08 DOI: 10.1038/d41573-025-00083-1

M. Teresa Villanueva

引用次数: 0

FDA approves cell-sheet-based gene therapy for severe skin disease FDA批准基于细胞薄片的基因疗法治疗严重皮肤病

IF 101.8 1区医学

Nature Reviews. Drug Discovery Pub Date : 2025-05-07 DOI: 10.1038/d41573-025-00082-2

Asher Mullard

引用次数: 0

FDA approves J&J’s FcRn blocker for generalized myasthenia gravis FDA批准强生FcRN阻滞剂治疗广泛性重症肌无力

IF 101.8 1区医学

Nature Reviews. Drug Discovery Pub Date : 2025-05-07 DOI: 10.1038/d41573-025-00081-3

Asher Mullard

引用次数: 0

Lasso peptide targets drug-resistant bacteria Lasso肽靶向耐药细菌

IF 101.8 1区医学

Nature Reviews. Drug Discovery Pub Date : 2025-05-02 DOI: 10.1038/d41573-025-00075-1

Sarah Crunkhorn

引用次数: 0

Targeting RNA structure to treat prostate cancer 靶向RNA结构治疗前列腺癌

IF 101.8 1区医学

Nature Reviews. Drug Discovery Pub Date : 2025-05-02 DOI: 10.1038/d41573-025-00077-z

Sarah Crunkhorn

引用次数: 0

Application of new approach methodologies for nonclinical safety assessment of drug candidates 新方法方法在候选药物非临床安全性评估中的应用

IF 101.8 1区医学

Nature Reviews. Drug Discovery Pub Date : 2025-05-02 DOI: 10.1038/s41573-025-01182-9

Mario Beilmann, Karissa Adkins, Harrie C. M. Boonen, Philip Hewitt, Wenyue Hu, Robert Mader, Susanne Moore, Payal Rana, Thomas Steger-Hartmann, Remi Villenave, Terry van Vleet

{"title":"Application of new approach methodologies for nonclinical safety assessment of drug candidates","authors":"Mario Beilmann, Karissa Adkins, Harrie C. M. Boonen, Philip Hewitt, Wenyue Hu, Robert Mader, Susanne Moore, Payal Rana, Thomas Steger-Hartmann, Remi Villenave, Terry van Vleet","doi":"10.1038/s41573-025-01182-9","DOIUrl":"10.1038/s41573-025-01182-9","url":null,"abstract":"The development of new approach methodologies (NAMs) and advances with in vitro testing systems have prompted revisions in regulatory guidelines and inspired dedicated in vitro/ex vivo studies for nonclinical safety assessment. This Review by a safety reflection initiative subgroup of the European Federation of Pharmaceutical Industries and Associations (EFPIA)/Preclinical Development Expert Group (PDEG) summarizes the current state and potential application of in vitro studies using human-derived material for safety assessment in drug development. It focuses on case studies from recent projects in which animal models alone proved to be limited or inadequate for safety testing. It further highlights four categories of drug candidates for which alternative in vitro approaches are applicable and discusses progress in using in vitro testing solutions for safety assessment in these categories. Finally, the article highlights new risk assessment strategies, initiatives and consortia promoting the advancement of NAMs. This collective work is meant to encourage the use of NAMs for more human-relevant safety assessment, which should ultimately result in reduced animal testing for drug development. New approach methodologies (NAMs) offer the promise of greater predictivity of potential safety risks of drug candidates, especially for newer types of therapeutics for which animal models alone have limited or no applicability for safety testing. This article identifies four categories of drug candidate for which NAMs are applicable and discusses progress in their use based on case studies from recent projects, as well as initiatives to promote the advancement and use of NAMs for more human-relevant safety assessment.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"24 9","pages":"705-725"},"PeriodicalIF":101.8,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143901259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TIM-3 regulates microglial function TIM-3调节小胶质细胞功能

IF 101.8 1区医学

Nature Reviews. Drug Discovery Pub Date : 2025-05-02 DOI: 10.1038/d41573-025-00078-y

Sarah Crunkhorn

引用次数: 0

Understanding LAG3 immune checkpoint function 了解LAG3免疫检查点功能

IF 101.8 1区医学

Nature Reviews. Drug Discovery Pub Date : 2025-05-02 DOI: 10.1038/d41573-025-00076-0

Sarah Crunkhorn

引用次数: 0